SLC20A2 and bilateral striopallidodentate calcinosis: Furthermore, findings of reduced bone mineralization in heterozygous Slc20a2+/– mice (Fig. 4, Supporting Fig. S6) and a trend for a gene dose effect on bone strength (Fig. 3, Supporting Figs. S4 and S5) suggest that careful consideration of fracture risk is required in PFBC patients as it may be greater than that predicted by BMD assessment given the profound effect on bone quality observed in homozygous Slc20a2–/– mice (Fig. 4).